Delve Bio Raises £35m for mNGS Infectious Disease Diagnostics

With $35 million successfully raised in Series A funding, Delve Bio establishes itself as a global leader in metagenomic next-generation sequencing (mNGS) for infectious diseases.

The capital will be used to market the business’ mNGS infectious disease diagnostic and develop a series of next-generation tests.

Chief Executive Officer of Delve, Bradley Murray, said that “while genomic testing has been transformative for oncology, rare disease and women’s health, infectious disease has been largely overlooked.”

Delve Bio was formed “with the vision of bringing infectious disease diagnostics into the genomics era, enabling patients with complex – and often life threatening – infections, to get a definitive diagnosis.”

For a long time, there has been a pattern whereby disease identification and diagnosis has focused on screening for a small fraction of pathogens. This comes with its own problems such as longer periods spent in hospitals, subsequent additional examinations, and even unsuitable treatment options.

By concurrently identifying pathogens, viruses, and fungi in just one patient sample using Delve’s mNGS diagnostic technology, the pathogen at the root of the problem may be correctly determined.

One of Delve’s co-founders, Joe DeRisi, expressed that they “firmly believe mNGS delivers the most conclusive, unbiased and actionable diagnosis of infectious disease.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.